Identification

Name
Selegiline
Accession Number
DB01037  (APRD00525)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Structure
Thumb
Synonyms
  • (−)-selegiline
  • L-Deprenalin
  • Selegilina
  • Selegilinum
Product Ingredients
IngredientUNIICASInChI Key
Selegiline hydrochloride6W731X367Q14611-52-0IYETZZCWLLUHIJ-UTONKHPSSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EldeprylCapsule5 mg/1OralMylan Specialty1996-05-15Not applicableUs
Eldepryl - 5mg TabTablet5 mgOralDraxis Health Inc.1997-09-022004-09-23Canada
Eldepryl Tab 5mgTablet5 mgOralDeprenyl Research Ltd.1990-12-311997-07-10Canada
EmsamPatch12 mg/24hTransdermalMylan Specialty2006-02-27Not applicableUs
EmsamPatch9 mg/24hTransdermalMylan Specialty2006-02-27Not applicableUs
EmsamPatch6 mg/24hTransdermalMylan Specialty2006-02-27Not applicableUs
Med SelegilineTablet5 mgOralMedican Pharma Incorporated1999-06-302011-03-29Canada
SelegilineTablet5 mgOralPharmel Inc1998-09-032016-10-25Canada
Selegiline-5Tablet5 mgOralPro Doc Limitee1998-03-252010-07-13Canada
ZelaparTablet, orally disintegrating1.25 mg/1OralValeant Pharmaceuticals North America2006-06-14Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-selegilineTablet5 mgOralApotex Corporation1997-02-13Not applicableCanada
Dom-selegilineTablet5 mgOralDominion Pharmacal1998-09-172016-10-25Canada
Mylan-selegilineTablet5 mgOralMylan Pharmaceuticals1997-04-09Not applicableCanada
Nu-selegilineTablet5 mgOralNu Pharm Inc1997-05-282012-09-04Canada
PMS-selegilineTablet5 mgOralPharmascience Inc1998-06-042016-10-28Canada
Selegiline HydrochlorideCapsule5 mg/1OralGolden State Medical Supply2006-11-04Not applicableUs67253 0700 06 nlmimage10 bb0edd86
Selegiline HydrochlorideCapsule5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1997-07-15Not applicableUs
Selegiline HydrochlorideTablet5 mg/1OralMayne Pharma2014-05-242019-07-31Us
Selegiline HydrochlorideTablet5 mg/1OralApotex Corporation1997-07-06Not applicableUs
Selegiline HydrochlorideCapsule5 mg/1OralCarilion Materials Management2006-11-04Not applicableUs
International/Other Brands
Carbex / Jumex
Categories
UNII
2K1V7GP655
CAS number
14611-51-9
Weight
Average: 187.286
Monoisotopic: 187.136099551
Chemical Formula
C13H17N
InChI Key
MEZLKOACVSPNER-GFCCVEGCSA-N
InChI
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
IUPAC Name
methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine
SMILES
C[C@H](CC1=CC=CC=C1)N(C)CC#C

Pharmacology

Indication

Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.

Associated Conditions
Pharmacodynamics

Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO-B. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.

Mechanism of action

Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.

TargetActionsOrganism
AAmine oxidase [flavin-containing] B
inhibitor
Human
NAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption

Rapidly absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

> 99.5%

Metabolism
Route of elimination
Not Available
Half life

1.2-2 hours

Clearance
Not Available
Toxicity

LD50=63 mg/kg (rats, IV)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Selegiline.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Selegiline.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Selegiline.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Selegiline.Experimental, Illicit
4-MethoxyamphetamineSelegiline may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Selegiline.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineSelegiline may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Abediterol.Investigational
AbirateroneThe serum concentration of Selegiline can be increased when it is combined with Abiraterone.Approved
AcarboseSelegiline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololSelegiline may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Selegiline can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Selegiline.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Selegiline.Experimental
AlbiglutideSelegiline may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Selegiline is combined with Aldesleukin.Approved
AlfentanilSelegiline may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Alfentanil.Approved, Illicit
AliskirenSelegiline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Selegiline.Approved, Investigational
AlogliptinSelegiline may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Selegiline.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Selegiline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Selegiline.Illicit
AlprenololSelegiline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Selegiline.Approved
AmbrisentanSelegiline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Selegiline.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Selegiline is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Selegiline is combined with Amiloride.Approved
AmineptineSelegiline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneSelegiline may increase the orthostatic hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Amisulpride.Approved, Investigational
AmitriptylineSelegiline may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideSelegiline may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineSelegiline may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Selegiline.Approved, Illicit
AmoxapineSelegiline may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Selegiline is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Selegiline.Approved, Illicit, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Selegiline is combined with Amyl Nitrite.Approved
ApalutamideThe serum concentration of Selegiline can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Selegiline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Selegiline is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Selegiline can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Selegiline.Approved, Investigational
ArmodafinilThe metabolism of Selegiline can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Selegiline.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Selegiline.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Asenapine.Approved
AtazanavirThe metabolism of Selegiline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololSelegiline may increase the hypotensive activities of Atenolol.Approved
AtomoxetineSelegiline may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineThe risk or severity of hypertension can be increased when Selegiline is combined with Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Azaperone.Investigational, Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Selegiline is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Selegiline can be decreased when combined with Azithromycin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Selegiline.Experimental
BarbitalBarbital may increase the hypotensive activities of Selegiline.Illicit
BarnidipineSelegiline may increase the orthostatic hypotensive activities of Barnidipine.Approved
BenazeprilSelegiline may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideSelegiline may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinSelegiline may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Benperidol.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Selegiline.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Selegiline.Approved
BepridilSelegiline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Selegiline.Approved, Investigational
BetaxololSelegiline may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineSelegiline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Selegiline is combined with Bezafibrate.Approved, Investigational
BietaserpineSelegiline may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Selegiline is combined with Bifeprunox.Investigational
BimatoprostSelegiline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololSelegiline may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Bitolterol.Withdrawn
BoceprevirThe metabolism of Selegiline can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Selegiline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Selegiline can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Selegiline.Approved
BQ-123Selegiline may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Selegiline.Approved, Investigational
BretyliumSelegiline may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Selegiline.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brimonidine.Approved
BrofaromineSelegiline may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Selegiline.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Selegiline.Approved
BumetanideThe risk or severity of adverse effects can be increased when Selegiline is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Selegiline.Approved, Investigational
BupranololSelegiline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Selegiline.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Selegiline is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Selegiline is combined with Buspirone.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Selegiline.Approved, Illicit, Vet Approved
ButriptylineSelegiline may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Selegiline.Approved
CadralazineSelegiline may increase the hypotensive activities of Cadralazine.Experimental
CafedrineSelegiline may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Selegiline can be decreased when combined with Caffeine.Approved
CanagliflozinSelegiline may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanSelegiline may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilSelegiline may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilSelegiline may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe metabolism of Selegiline can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilSelegiline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Selegiline.Approved, Investigational
CarbamazepineThe metabolism of Selegiline can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Selegiline.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Selegiline.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Selegiline.Approved, Investigational
CaroxazoneSelegiline may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololSelegiline may increase the hypotensive activities of Carteolol.Approved
CarvedilolSelegiline may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Selegiline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololSelegiline may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Selegiline can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Selegiline.Approved
ChloramphenicolThe metabolism of Selegiline can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlormadinoneThe serum concentration of Selegiline can be increased when it is combined with Chlormadinone.Experimental
ChlorothiazideSelegiline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Selegiline.Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Selegiline.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Selegiline.Approved, Investigational, Vet Approved
ChlorpropamideSelegiline may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneSelegiline may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Selegiline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineSelegiline may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilSelegiline may increase the hypotensive activities of Cilazapril.Approved
CilnidipineSelegiline may increase the orthostatic hypotensive activities of Cilnidipine.Approved, Investigational
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Selegiline.Approved, Investigational
CiprofloxacinThe metabolism of Selegiline can be decreased when combined with Ciprofloxacin.Approved, Investigational
CirazolineSelegiline may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Selegiline.Approved
ClarithromycinThe metabolism of Selegiline can be decreased when combined with Clarithromycin.Approved
ClemastineSelegiline may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineSelegiline may increase the orthostatic hypotensive activities of Clevidipine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Selegiline is combined with Clindamycin.Approved, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Selegiline.Approved, Investigational
ClomipramineSelegiline may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineSelegiline may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Selegiline is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Selegiline can be decreased when combined with Clopidogrel.Approved
CloranololSelegiline may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Selegiline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Selegiline.Approved
CobicistatThe metabolism of Selegiline can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Selegiline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Selegiline.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Selegiline.Approved, Investigational
CrisaboroleThe metabolism of Selegiline can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Selegiline can be decreased when combined with Crizotinib.Approved
CryptenamineSelegiline may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe metabolism of Selegiline can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Selegiline.Approved
CyclopenthiazideSelegiline may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Selegiline is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideSelegiline may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineSelegiline may increase the anticholinergic activities of Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Selegiline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Selegiline.Approved
DabrafenibThe serum concentration of Selegiline can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinSelegiline may increase the orthostatic hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Selegiline.Investigational
DarunavirThe metabolism of Selegiline can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Selegiline can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinSelegiline may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Selegiline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilSelegiline may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Selegiline can be decreased when combined with Delavirdine.Approved
DeserpidineSelegiline may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Selegiline.Approved
DesipramineSelegiline may increase the serotonergic activities of Desipramine.Approved, Investigational
DesogestrelThe serum concentration of Selegiline can be increased when it is combined with Desogestrel.Approved
DesvenlafaxineSelegiline may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Selegiline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Selegiline.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateSelegiline may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DexniguldipineSelegiline may increase the hypotensive activities of Dexniguldipine.Experimental
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Selegiline.Approved, Illicit
DextromethorphanThe risk or severity of serotonin syndrome can be increased when Selegiline is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Selegiline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Selegiline.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Selegiline.Approved, Investigational
DiazoxideSelegiline may increase the hypotensive activities of Diazoxide.Approved
DibenzepinSelegiline may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Selegiline is combined with Diclofenamide.Approved, Investigational
DienogestThe serum concentration of Selegiline can be increased when it is combined with Dienogest.Approved
DiethylnorspermineSelegiline may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionThe risk or severity of adverse effects can be increased when Selegiline is combined with Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Selegiline can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydralazineSelegiline may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Selegiline.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Selegiline.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Selegiline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Selegiline.Experimental, Illicit
DiltiazemSelegiline may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Selegiline.Approved
DimetacrineSelegiline may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Selegiline is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Selegiline.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Selegiline.Approved, Illicit
DipivefrinSelegiline may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Dipyridamole.Approved
DisopyramideSelegiline may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Selegiline is combined with Disulfiram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Selegiline.Approved, Investigational
DomperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideSelegiline may increase the hypotensive activities of Dorzolamide.Approved
DosulepinSelegiline may increase the serotonergic activities of Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dotarizine.Investigational
DoxapramSelegiline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinSelegiline may increase the hypotensive activities of Doxazosin.Approved
DoxepinSelegiline may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Selegiline is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Selegiline.Approved, Investigational
DoxorubicinThe metabolism of Selegiline can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Selegiline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Selegiline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Selegiline.Experimental
DronedaroneThe metabolism of Selegiline can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Selegiline can be increased when it is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Selegiline.Experimental, Illicit
DroxidopaSelegiline may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideSelegiline may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineSelegiline may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Selegiline.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Selegiline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Selegiline.Approved
EfavirenzThe metabolism of Selegiline can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineSelegiline may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Selegiline.Approved, Investigational
EmpagliflozinSelegiline may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilSelegiline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSelegiline may increase the hypotensive activities of Enalaprilat.Approved
EndralazineSelegiline may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Selegiline.Approved, Investigational
EnzalutamideThe serum concentration of Selegiline can be decreased when it is combined with Enzalutamide.Approved
EpanololSelegiline may increase the hypotensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Eperisone.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Selegiline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineSelegiline may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Eplerenone.Approved
EpoprostenolSelegiline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanSelegiline may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.Approved
ErgonovineSelegiline may increase the hypertensive activities of Ergonovine.Approved
ErgotamineSelegiline may increase the hypertensive activities of Ergotamine.Approved
ErythromycinThe metabolism of Selegiline can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Selegiline.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Selegiline can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Selegiline is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Selegiline can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Selegiline can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Selegiline can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Selegiline can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Selegiline is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Selegiline is combined with Etafedrine.Approved
EthanolSelegiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Selegiline can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Selegiline.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Selegiline.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Selegiline can be increased when it is combined with Ethynodiol diacetate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Selegiline.Approved
EtonogestrelThe serum concentration of Selegiline can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoperidoneSelegiline may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Selegiline.Illicit, Vet Approved
EtravirineThe metabolism of Selegiline can be decreased when combined with Etravirine.Approved
ExenatideSelegiline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineSelegiline may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineSelegiline may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamSelegiline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of hypertension, serotonin syndrome, and CNS depression can be increased when Selegiline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSelegiline may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Selegiline.Approved, Investigational
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Selegiline.Approved, Investigational
FloxuridineThe metabolism of Selegiline can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Selegiline can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Selegiline.Approved
FluorouracilThe metabolism of Selegiline can be decreased when combined with Fluorouracil.Approved
FluoxetineSelegiline may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Selegiline.Approved
FluvoxamineSelegiline may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Selegiline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Selegiline can be increased when it is combined with Fosaprepitant.Approved
FosinoprilSelegiline may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Selegiline can be increased when combined with Fosphenytoin.Approved, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Selegiline.Approved, Investigational
FurazolidoneSelegiline may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideSelegiline may increase the orthostatic hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Selegiline can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Selegiline.Approved, Investigational
GemfibrozilThe metabolism of Selegiline can be decreased when combined with Gemfibrozil.Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Selegiline.Experimental
GestodeneThe serum concentration of Selegiline can be increased when it is combined with Gestodene.Approved, Investigational
GestrinoneThe serum concentration of Selegiline can be increased when it is combined with Gestrinone.Approved
GliclazideSelegiline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSelegiline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSelegiline may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideSelegiline may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Selegiline.Approved, Investigational
GuanabenzSelegiline may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelSelegiline may increase the hypotensive activities of Guanadrel.Approved
GuanazodineSelegiline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineSelegiline may increase the hypotensive activities of Guanethidine.Approved
GuanfacineSelegiline may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorSelegiline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSelegiline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSelegiline may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Selegiline.Approved, Vet Approved
HarmalineSelegiline may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Selegiline.Approved, Illicit, Investigational
HexamethoniumSelegiline may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Selegiline.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineSelegiline may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineSelegiline may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideSelegiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneSelegiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideSelegiline may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Selegiline.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Selegiline.Approved
Hydroxyprogesterone caproateThe serum concentration of Selegiline can be increased when it is combined with Hydroxyprogesterone caproate.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Selegiline.Approved
IdelalisibThe metabolism of Selegiline can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Selegiline.Approved, Investigational
ImatinibThe metabolism of Selegiline can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Selegiline.Investigational
ImipramineSelegiline may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Indacaterol.Approved
IndalpineSelegiline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideSelegiline may increase the hypotensive activities of Indapamide.Approved
IndenololSelegiline may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Selegiline can be decreased when combined with Indinavir.Approved
IndoraminSelegiline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartSelegiline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSelegiline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSelegiline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSelegiline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSelegiline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSelegiline may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Selegiline.Approved
Ioflupane I-123Selegiline may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleSelegiline may increase the serotonergic activities of Iprindole.Experimental
IproclozideSelegiline may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidSelegiline may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanThe metabolism of Selegiline can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Selegiline can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Selegiline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidSelegiline may increase the hypertensive activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Selegiline.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Selegiline is combined with Isometheptene.Approved
IsoniazidThe metabolism of Selegiline can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoprenaline.Approved, Investigational
Isosorbide DinitrateSelegiline may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Selegiline is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isoxsuprine.Approved, Withdrawn
IsradipineSelegiline may increase the hypotensive activities of Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Selegiline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Selegiline can be increased when it is combined with Ivacaftor.Approved
KetanserinSelegiline may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Selegiline.Approved, Investigational
KetoconazoleThe metabolism of Selegiline can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Selegiline.Approved, Nutraceutical, Withdrawn
LabetalolSelegiline may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Selegiline.Approved, Investigational
LapatinibThe metabolism of Selegiline can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostSelegiline may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Selegiline.Approved
LeflunomideThe metabolism of Selegiline can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineSelegiline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Selegiline.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Selegiline is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Selegiline.Approved, Investigational
LevodopaThe risk or severity of orthostatic hypotension can be increased when Selegiline is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Selegiline.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Selegiline.Approved, Investigational
LevonordefrinSelegiline may increase the hypertensive activities of Levonordefrin.Approved
LevonorgestrelThe serum concentration of Selegiline can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Selegiline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Selegiline is combined with Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Selegiline.Approved, Investigational
LidocaineThe metabolism of Selegiline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Selegiline is combined with Linezolid.Approved, Investigational
LinsidomineSelegiline may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideSelegiline may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Selegiline.Approved, Investigational
LisinoprilSelegiline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Selegiline.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.Experimental
LobeglitazoneThe metabolism of Selegiline can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Selegiline.Illicit
LofepramineSelegiline may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Selegiline.Approved, Investigational
LopinavirThe metabolism of Selegiline can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Selegiline.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Selegiline is combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Selegiline can be increased when it is combined with Lorpiprazole.Approved
LosartanSelegiline may increase the hypotensive activities of Losartan.Approved
LovastatinThe metabolism of Selegiline can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Selegiline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Selegiline can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.Approved, Investigational
LynestrenolThe serum concentration of Selegiline can be increased when it is combined with Lynestrenol.Approved, Investigational
MacitentanSelegiline may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Selegiline can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium Trisilicate.Approved
ManidipineSelegiline may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Selegiline is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Maprotiline.Approved, Investigational
MebanazineSelegiline may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineSelegiline may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminSelegiline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Selegiline.Approved
Medroxyprogesterone acetateThe serum concentration of Selegiline can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe serum concentration of Selegiline can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelitracenSelegiline may increase the serotonergic activities of Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Melperone.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Selegiline.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Selegiline.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Selegiline.Experimental
MequitazineSelegiline may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Selegiline can be increased when it is combined with Mestranol.Approved
MetaraminolSelegiline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminSelegiline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Selegiline.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Selegiline.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Selegiline is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Selegiline.Approved
MethoserpidineSelegiline may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methotrimeprazine.Approved, Investigational
MethoxamineSelegiline may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Selegiline.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Selegiline.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Selegiline is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of hypertension can be increased when Selegiline is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Selegiline.Experimental
Methylene blueSelegiline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateSelegiline may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Selegiline.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Selegiline.Approved
MetipranololSelegiline may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.Approved, Investigational
MetolazoneSelegiline may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Selegiline.Approved, Investigational
MexiletineThe metabolism of Selegiline can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe risk or severity of adverse effects can be increased when Selegiline is combined with Mianserin.Approved, Investigational
MibefradilSelegiline may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Selegiline can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidodrineSelegiline may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Selegiline.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Selegiline can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Selegiline can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolSelegiline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Selegiline.Approved, Investigational
MinaprineSelegiline may increase the hypertensive activities of Minaprine.Approved
MinoxidilSelegiline may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Selegiline can be decreased when it is combined with Mitotane.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Selegiline.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Selegiline is combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Selegiline can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilSelegiline may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Moperone.Experimental
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Selegiline.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mosapramine.Experimental
MoxonidineSelegiline may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineSelegiline may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Selegiline.Approved, Investigational
NadololSelegiline may increase the hypotensive activities of Nadolol.Approved
NaftopidilSelegiline may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Selegiline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Selegiline.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Selegiline.Investigational
NaphazolineSelegiline may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Selegiline.Approved, Investigational
NateglinideSelegiline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololSelegiline may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Selegiline.Approved, Withdrawn
NelfinavirThe metabolism of Selegiline can be decreased when combined with Nelfinavir.Approved
NeomycinThe risk or severity of adverse effects can be increased when Selegiline is combined with Neomycin.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Selegiline is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Selegiline can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Selegiline can be increased when combined with Nevirapine.Approved
NialamideSelegiline may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineSelegiline may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Selegiline.Approved, Investigational
NifedipineSelegiline may increase the orthostatic hypotensive activities of Nifedipine.Approved
NiguldipineSelegiline may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Selegiline can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineSelegiline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineSelegiline may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineSelegiline may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineSelegiline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Selegiline.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Selegiline is combined with Nitroglycerin.Approved, Investigational
NitroprussideSelegiline may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Selegiline is combined with Nitrous acid.Approved, Investigational
Nomegestrol acetateThe serum concentration of Selegiline can be increased when it is combined with Nomegestrol acetate.Approved, Investigational
NorelgestrominThe serum concentration of Selegiline can be increased when it is combined with Norelgestromin.Approved, Investigational
NorepinephrineSelegiline may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Selegiline can be increased when it is combined with Norethisterone.Approved
NorethynodrelThe serum concentration of Selegiline can be increased when it is combined with Norethynodrel.Approved
NorgestimateThe serum concentration of Selegiline can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Selegiline can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Selegiline can be increased when it is combined with Norgestrienone.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Selegiline.Approved, Illicit
NortriptylineSelegiline may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Selegiline.Approved, Investigational
OctamoxinSelegiline may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineSelegiline may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Selegiline can be decreased when combined with Olaparib.Approved
OlmesartanSelegiline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Olodaterol.Approved
OmapatrilatSelegiline may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Selegiline.Approved
OpipramolSelegiline may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Selegiline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Selegiline can be increased when it is combined with Osimertinib.Approved
OxcarbazepineOxcarbazepine may increase the serotonergic activities of Selegiline.Approved
OxprenololSelegiline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneSelegiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineSelegiline may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Selegiline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Selegiline is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Selegiline.Approved, Vet Approved
PalbociclibThe serum concentration of Selegiline can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Selegiline.Approved, Investigational
PantoprazoleThe metabolism of Selegiline can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Selegiline is combined with Papaverine.Approved, Investigational
PargylineSelegiline may increase the hypertensive activities of Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Selegiline is combined with Paromomycin.Approved, Investigational
ParoxetineSelegiline may increase the serotonergic activities of Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Selegiline.Approved
Peginterferon alfa-2bThe serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololSelegiline may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Selegiline is combined with Penfluridol.Experimental
PentamidineSelegiline may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Selegiline.Approved, Vet Approved
PentobarbitalThe metabolism of Selegiline can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumSelegiline may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perazine.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilSelegiline may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Selegiline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perphenazine.Approved
PethidineSelegiline may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Selegiline is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Selegiline.Experimental
PhendimetrazineSelegiline may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Selegiline.Approved
PheniprazineSelegiline may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Selegiline.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Selegiline.Experimental
PhenoxybenzamineSelegiline may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineSelegiline may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Selegiline.Approved, Illicit
PhentolamineSelegiline may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineSelegiline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Selegiline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Selegiline can be increased when combined with Phenytoin.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Selegiline.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Selegiline.Investigational
PimozideThe risk or severity of adverse effects can be increased when Selegiline is combined with Pimozide.Approved
PinacidilSelegiline may increase the hypotensive activities of Pinacidil.Approved
PindololSelegiline may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Selegiline can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Selegiline.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Selegiline.Approved, Investigational
PirlindoleSelegiline may increase the hypertensive activities of Pirlindole.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Selegiline.Approved, Investigational
PivhydrazineSelegiline may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenSelegiline may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorSelegiline may increase the hypotensive activities of Platelet Activating Factor.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Selegiline is combined with Polymyxin B Sulfate.Approved, Vet Approved
PosaconazoleThe metabolism of Selegiline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleSelegiline may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideSelegiline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinSelegiline may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Selegiline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Selegiline can be increased when combined with Primidone.Approved, Vet Approved
ProcaineSelegiline may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineSelegiline may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promethazine.Approved, Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Selegiline.Approved, Investigational, Vet Approved
PropranololSelegiline may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Selegiline is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Selegiline is combined with Protokylol.Approved, Vet Approved
ProtriptylineSelegiline may increase the serotonergic activities of Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Selegiline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Selegiline.Approved
PyrantelThe risk or severity of adverse effects can be increased when Selegiline is combined with Pyrantel.Approved, Vet Approved
PyrimethamineThe metabolism of Selegiline can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe serum concentration of Selegiline can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineSelegiline may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinaprilSelegiline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuingestanolThe serum concentration of Selegiline can be increased when it is combined with Quingestanol.Experimental
QuinineThe metabolism of Selegiline can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Selegiline can be decreased when combined with Rabeprazole.Approved, Investigational
RacepinephrineSelegiline may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Raclopride.Investigational
RamiprilSelegiline may increase the hypotensive activities of Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Selegiline.Approved, Investigational
RasagilineSelegiline may increase the hypertensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Selegiline.Approved
RemikirenSelegiline may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.Approved, Withdrawn
RepaglinideSelegiline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineSelegiline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Selegiline is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Selegiline can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Selegiline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Selegiline can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Selegiline.Approved, Investigational
RilmenidineSelegiline may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatSelegiline may increase the hypotensive activities of Riociguat.Approved
RisperidoneSelegiline may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Selegiline is combined with Ritanserin.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Selegiline.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Selegiline.Approved
RopiniroleSelegiline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Selegiline.Approved
RosiglitazoneSelegiline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Selegiline.Approved
RucaparibThe metabolism of Selegiline can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Selegiline.Approved
SafrazineSelegiline may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Salmeterol.Approved
SaprisartanSelegiline may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Selegiline can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Selegiline can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinSelegiline may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Selegiline.Approved, Investigational
SecobarbitalThe metabolism of Selegiline can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagSelegiline may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Selegiline is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Selegiline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Selegiline is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Selegiline can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Selegiline.Approved
SiltuximabThe serum concentration of Selegiline can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Selegiline can be increased when it is combined with Simeprevir.Approved
SitagliptinSelegiline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanSelegiline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Selegiline can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Selegiline is combined with Sotalol.Approved
SpiraprilSelegiline may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSelegiline may increase the orthostatic hypotensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Selegiline can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Selegiline can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Selegiline is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Selegiline.Approved, Investigational
SulfadiazineThe metabolism of Selegiline can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Selegiline can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Selegiline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Sultopride.Experimental
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Selegiline.Approved, Investigational
SunitinibSelegiline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololSelegiline may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Selegiline can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Selegiline is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Selegiline.Approved
Tedizolid phosphateTedizolid Phosphate may increase the serotonergic activities of Selegiline.Approved
TelaprevirThe metabolism of Selegiline can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Selegiline can be decreased when combined with Telithromycin.Approved
TelmisartanSelegiline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilSelegiline may increase the hypotensive activities of Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Selegiline can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Selegiline is combined with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.Approved
TerlipressinSelegiline may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Selegiline.Investigational
TetrahydropalmatineSelegiline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineSelegiline may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Selegiline is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineSelegiline may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Selegiline can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Selegiline.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Selegiline.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Selegiline.Approved, Withdrawn
ThiotepaThe metabolism of Selegiline can be decreased when combined with Thiotepa.Approved, Investigational
ThiothixeneThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Selegiline.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Tiapride.Approved, Investigational
TiboloneSelegiline may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Selegiline can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Selegiline can be decreased when combined with Ticlopidine.Approved
TicrynafenSelegiline may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Selegiline.Experimental
TimololSelegiline may increase the hypotensive activities of Timolol.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Selegiline.Approved, Investigational
TocilizumabThe serum concentration of Selegiline can be decreased when it is combined with Tocilizumab.Approved
TolazamideSelegiline may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineSelegiline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Selegiline can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Selegiline.Approved, Withdrawn
TolonidineSelegiline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneSelegiline may increase the hypertensive activities of Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Selegiline.Approved
TopiroxostatThe metabolism of Selegiline can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Selegiline.Approved, Investigational
TorasemideSelegiline may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of serotonin syndrome and seizure can be increased when Selegiline is combined with Tramadol.Approved, Investigational
TrandolaprilSelegiline may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Selegiline.Approved, Investigational
TravoprostSelegiline may increase the hypotensive activities of Travoprost.Approved
TrazodoneSelegiline may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilSelegiline may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Selegiline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Selegiline is combined with Triamterene.Approved
TrichlormethiazideSelegiline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Selegiline is combined with Triflupromazine.Approved, Vet Approved
TrimazosinSelegiline may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Selegiline is combined with Trimethadione.Approved
TrimethaphanSelegiline may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe metabolism of Selegiline can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineSelegiline may increase the serotonergic activities of Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Selegiline.Approved, Investigational
UlipristalThe serum concentration of Selegiline can be increased when it is combined with Ulipristal.Approved
UnoprostoneSelegiline may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilSelegiline may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Selegiline.Approved, Investigational
ValsartanThe metabolism of Selegiline can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Selegiline is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Selegiline is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Selegiline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineSelegiline may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Selegiline is combined with Veralipride.Experimental
VerapamilSelegiline may increase the orthostatic hypotensive activities of Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Selegiline is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Selegiline.Approved
VincamineSelegiline may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Selegiline.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Selegiline is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Selegiline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Selegiline.Approved, Investigational
XipamideSelegiline may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSelegiline may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZafirlukastThe metabolism of Selegiline can be decreased when combined with Zafirlukast.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Selegiline.Approved
ZimelidineSelegiline may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Selegiline.Approved
ZofenoprilSelegiline may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Selegiline.Approved, Investigational
ZolpidemSelegiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Selegiline.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Selegiline can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Food increases the oral bioavailability by 3-5 fold.

References

Synthesis Reference

Silvia Ott-Dembrowski, Richard Cyrus, Jorg Schmidt, Hans Waiblinger, "Preparation of selegiline." U.S. Patent US5847216, issued March, 1962.

US5847216
General References
  1. Engberg G, Elebring T, Nissbrandt H: Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. [PubMed:1658311]
  2. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956]
  3. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926]
  4. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016]
  5. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145]
  6. Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. [PubMed:18311418]
  7. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
External Links
Human Metabolome Database
HMDB15171
KEGG Drug
D03731
KEGG Compound
C07245
PubChem Compound
26757
PubChem Substance
46507655
ChemSpider
24930
BindingDB
15579
ChEBI
9086
ChEMBL
CHEMBL972
Therapeutic Targets Database
DAP000579
PharmGKB
PA451316
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Selegiline
ATC Codes
N04BD01 — Selegiline
AHFS Codes
  • 28:36.32 — Monoamine Oxidase B Inhibitors
FDA label
Download (189 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentSchizophrenic Disorders1
1CompletedTreatmentCocaine-Related Disorders1
1Unknown StatusTreatmentAmphetamine-Related Disorders1
2CompletedTreatmentCocaine Use Disorders1
2CompletedTreatmentCocaine-Related Disorders3
2CompletedTreatmentCognition Disorders / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentCognitive Disorders / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentMarijuana Abuse1
2CompletedTreatmentNicotine Dependence1
2CompletedTreatmentTobacco Use Cessation1
2CompletedTreatmentTobacco Use Disorders1
3CompletedTreatmentBorderline Personality Disorder (BPD)1
3CompletedTreatmentCocaine-Related Disorders1
4CompletedDiagnosticHealthy Volunteers1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentParkinson's Disease (PD)2
4RecruitingTreatmentErectile Dysfunction (ED) / Parkinson's Disease (PD)1
4TerminatedTreatmentDepression, Bipolar1
Not AvailableCompletedTreatmentCognitive Disorders / Human Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alphapharm Party Ltd.
  • Apotex Inc.
  • Bristol-Myers Squibb Co.
  • Catalent Pharma Solutions
  • DAHI Animal Health Inc.
  • DAVA Pharmaceuticals
  • Dey Pharma LP
  • Draxis Specialty Pharmaceuticals Inc.
  • Endo Pharmaceuticals Inc.
  • Heartland Repack Services LLC
  • Legacy Pharmaceuticals Packaging LLC
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Par Pharmaceuticals
  • Physicians Total Care Inc.
  • Resource Optimization and Innovation LLC
  • Somerset Pharmaceuticals Inc.
  • Standard Chem and Pharm Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Ultratab Labs Inc.
  • Valeant Ltd.
Dosage forms
FormRouteStrength
TabletOral5 mg
PatchTransdermal12 mg/24h
PatchTransdermal6 mg/24h
PatchTransdermal9 mg/24h
CapsuleOral5 mg/1
TabletOral5 mg/1
Tablet, orally disintegratingOral1.25 mg/1
Prices
Unit descriptionCostUnit
Emsam 30 12 mg/24hr Patches Box627.1USD box
Emsam 30 6 mg/24hr Patches Box627.1USD box
Emsam 30 9 mg/24hr Patches Box627.1USD box
Selegiline hcl powder127.3USD g
Eldepryl 30 5 mg capsule Box89.55USD box
Emsam 12 mg/24 hours patch20.1USD patch
Emsam 6 mg/24 hours patch20.1USD patch
Emsam 9 mg/24 hours patch20.1USD patch
Zelapar 1.25 mg odt tablet8.33USD tablet
Selegiline HCl 5 mg capsule2.4USD capsule
Selegiline hcl 5 mg tablet2.1USD tablet
Apo-Selegiline 5 mg Tablet1.33USD tablet
Mylan-Selegiline 5 mg Tablet1.33USD tablet
Novo-Selegiline 5 mg Tablet1.33USD tablet
Nu-Selegiline 5 mg Tablet1.33USD tablet
Pms-Selegiline 5 mg Tablet1.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5648093No1994-07-152014-07-15Us
US7150881No1998-06-122018-06-12Us
US7070808No1998-05-102018-05-10Us
US7638140No1998-05-102018-05-10Us
US6423342No1996-03-012016-03-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)141-142 °CNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0254 mg/mLALOGPS
logP3.08ALOGPS
logP2.85ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)8.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity61.35 m3·mol-1ChemAxon
Polarizability22.69 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier+0.9809
Caco-2 permeable+0.8453
P-glycoprotein substrateNon-substrate0.543
P-glycoprotein inhibitor INon-inhibitor0.9632
P-glycoprotein inhibitor IINon-inhibitor0.9779
Renal organic cation transporterInhibitor0.5327
CYP450 2C9 substrateNon-substrate0.7993
CYP450 2D6 substrateSubstrate0.6987
CYP450 3A4 substrateNon-substrate0.5671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9341
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9285
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9285
Ames testNon AMES toxic0.889
CarcinogenicityNon-carcinogens0.6567
BiodegradationNot ready biodegradable0.9767
Rat acute toxicity2.9199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8869
hERG inhibition (predictor II)Non-inhibitor0.8269
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / Trialkylamines / Acetylides / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Acetylide / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
terminal acetylenic compound, selegiline (CHEBI:9086)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48. [PubMed:1794016]
  3. Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22. [PubMed:9673855]
  4. Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11. [PubMed:12199263]
  5. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956]
  6. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926]
  7. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016]
  8. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145]
  9. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841]
  10. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422]
  11. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  12. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841]
  2. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422]
  3. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. [PubMed:18311418]
  2. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  3. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414]
  4. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Nirogi R, Palacharla RC, Mohammed AR, Manoharan A, Ponnamaneni RK, Bhyrapuneni G: Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20. doi: 10.1016/j.cbi.2015.01.028. Epub 2015 Feb 3. [PubMed:25656918]
  7. Sridar C, Kenaan C, Hollenberg PF: Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos. 2012 Dec;40(12):2256-66. doi: 10.1124/dmd.112.046979. Epub 2012 Aug 30. [PubMed:22936314]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583]
  2. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. [PubMed:17495414]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:48